471 related articles for article (PubMed ID: 30907317)
1. Characterization of Serum Exosomes from a Transgenic Mouse Model of Alzheimer's Disease.
Rosas-Hernandez H; Cuevas E; Raymick JB; Robinson BL; Ali SF; Hanig J; Sarkar S
Curr Alzheimer Res; 2019; 16(5):388-395. PubMed ID: 30907317
[TBL] [Abstract][Full Text] [Related]
2. The exosome of adipose-derived stem cells reduces β-amyloid pathology and apoptosis of neuronal cells derived from the transgenic mouse model of Alzheimer's disease.
Lee M; Ban JJ; Yang S; Im W; Kim M
Brain Res; 2018 Jul; 1691():87-93. PubMed ID: 29625119
[TBL] [Abstract][Full Text] [Related]
3. Ultrasound-mediated augmented exosome release from astrocytes alleviates amyloid-β-induced neurotoxicity.
Deng Z; Wang J; Xiao Y; Li F; Niu L; Liu X; Meng L; Zheng H
Theranostics; 2021; 11(9):4351-4362. PubMed ID: 33754065
[No Abstract] [Full Text] [Related]
4. Plasma neuronal exosomes serve as biomarkers of cognitive impairment in HIV infection and Alzheimer's disease.
Pulliam L; Sun B; Mustapic M; Chawla S; Kapogiannis D
J Neurovirol; 2019 Oct; 25(5):702-709. PubMed ID: 30610738
[TBL] [Abstract][Full Text] [Related]
5. Neutral Sphingomyelinase-2 Deficiency Ameliorates Alzheimer's Disease Pathology and Improves Cognition in the 5XFAD Mouse.
Dinkins MB; Enasko J; Hernandez C; Wang G; Kong J; Helwa I; Liu Y; Terry AV; Bieberich E
J Neurosci; 2016 Aug; 36(33):8653-67. PubMed ID: 27535912
[TBL] [Abstract][Full Text] [Related]
6. Cargo proteins of plasma astrocyte-derived exosomes in Alzheimer's disease.
Goetzl EJ; Mustapic M; Kapogiannis D; Eitan E; Lobach IV; Goetzl L; Schwartz JB; Miller BL
FASEB J; 2016 Nov; 30(11):3853-3859. PubMed ID: 27511944
[TBL] [Abstract][Full Text] [Related]
7. Amyloid-induced neurofibrillary tangle formation in Alzheimer's disease: insight from transgenic mouse and tissue-culture models.
Götz J; Schild A; Hoerndli F; Pennanen L
Int J Dev Neurosci; 2004 Nov; 22(7):453-65. PubMed ID: 15465275
[TBL] [Abstract][Full Text] [Related]
8. Human tau increases amyloid β plaque size but not amyloid β-mediated synapse loss in a novel mouse model of Alzheimer's disease.
Jackson RJ; Rudinskiy N; Herrmann AG; Croft S; Kim JM; Petrova V; Ramos-Rodriguez JJ; Pitstick R; Wegmann S; Garcia-Alloza M; Carlson GA; Hyman BT; Spires-Jones TL
Eur J Neurosci; 2016 Dec; 44(12):3056-3066. PubMed ID: 27748574
[TBL] [Abstract][Full Text] [Related]
9. Impaired Amyloid Beta Clearance and Brain Microvascular Dysfunction are Present in the Tg-SwDI Mouse Model of Alzheimer's Disease.
Rosas-Hernandez H; Cuevas E; Raymick JB; Robinson BL; Sarkar S
Neuroscience; 2020 Aug; 440():48-55. PubMed ID: 32450297
[TBL] [Abstract][Full Text] [Related]
10. Active full-length DNA Aβ
Rosenberg RN; Fu M; Lambracht-Washington D
Alzheimers Res Ther; 2018 Nov; 10(1):115. PubMed ID: 30454039
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy to improve cognition and reduce pathological species in an Alzheimer's disease mouse model.
Herline K; Prelli F; Mehta P; MacMurray C; Goñi F; Wisniewski T
Alzheimers Res Ther; 2018 Jun; 10(1):54. PubMed ID: 29914551
[TBL] [Abstract][Full Text] [Related]
12. [Development of SPECT Probes for In Vivo Imaging of β-Amyloid and Tau Aggregates in the Alzheimer's Disease Brain].
Watanabe H
Yakugaku Zasshi; 2017; 137(11):1361-1365. PubMed ID: 29093372
[TBL] [Abstract][Full Text] [Related]
13. Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model.
Fryer JD; Simmons K; Parsadanian M; Bales KR; Paul SM; Sullivan PM; Holtzman DM
J Neurosci; 2005 Mar; 25(11):2803-10. PubMed ID: 15772340
[TBL] [Abstract][Full Text] [Related]
14. Molecular and functional signatures in a novel Alzheimer's disease mouse model assessed by quantitative proteomics.
Kim DK; Park J; Han D; Yang J; Kim A; Woo J; Kim Y; Mook-Jung I
Mol Neurodegener; 2018 Jan; 13(1):2. PubMed ID: 29338754
[TBL] [Abstract][Full Text] [Related]
15. Soluble Conformers of Aβ and Tau Alter Selective Proteins Governing Axonal Transport.
Sherman MA; LaCroix M; Amar F; Larson ME; Forster C; Aguzzi A; Bennett DA; Ramsden M; Lesné SE
J Neurosci; 2016 Sep; 36(37):9647-58. PubMed ID: 27629715
[TBL] [Abstract][Full Text] [Related]
16. Mouse models of Alzheimer's disease: the long and filamentous road.
Phinney AL; Horne P; Yang J; Janus C; Bergeron C; Westaway D
Neurol Res; 2003 Sep; 25(6):590-600. PubMed ID: 14503012
[TBL] [Abstract][Full Text] [Related]
17. Effects of the superoxide dismutase/catalase mimetic EUK-207 in a mouse model of Alzheimer's disease: protection against and interruption of progression of amyloid and tau pathology and cognitive decline.
Clausen A; Xu X; Bi X; Baudry M
J Alzheimers Dis; 2012; 30(1):183-208. PubMed ID: 22406441
[TBL] [Abstract][Full Text] [Related]
18. Extra-virgin olive oil attenuates amyloid-β and tau pathologies in the brains of TgSwDI mice.
Qosa H; Mohamed LA; Batarseh YS; Alqahtani S; Ibrahim B; LeVine H; Keller JN; Kaddoumi A
J Nutr Biochem; 2015 Dec; 26(12):1479-90. PubMed ID: 26344778
[TBL] [Abstract][Full Text] [Related]
19. Effects of CX3CR1 and Fractalkine Chemokines in Amyloid Beta Clearance and p-Tau Accumulation in Alzheimer's Disease (AD) Rodent Models: Is Fractalkine a Systemic Biomarker for AD?
Merino JJ; Muñetón-Gómez V; Alvárez MI; Toledano-Díaz A
Curr Alzheimer Res; 2016; 13(4):403-12. PubMed ID: 26567742
[TBL] [Abstract][Full Text] [Related]
20. Relationship between ubiquilin-1 and BACE1 in human Alzheimer's disease and APdE9 transgenic mouse brain and cell-based models.
Natunen T; Takalo M; Kemppainen S; Leskelä S; Marttinen M; Kurkinen KMA; Pursiheimo JP; Sarajärvi T; Viswanathan J; Gabbouj S; Solje E; Tahvanainen E; Pirttimäki T; Kurki M; Paananen J; Rauramaa T; Miettinen P; Mäkinen P; Leinonen V; Soininen H; Airenne K; Tanzi RE; Tanila H; Haapasalo A; Hiltunen M
Neurobiol Dis; 2016 Jan; 85():187-205. PubMed ID: 26563932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
